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KEY POINTS
 Exercise Doppler echocardiography has been implemented for applications beyond coronary ar-
tery disease detection, but with a great variability of protocols to assess early stage pulmonary
vascular disease and/or left heart failure.
 The RIGHT heart international NETwork (“RIGHT-NET”) is a large prospective clinical and echocar-
diography observational multicenter study.
 Aims of the RIGHT-NET: a) define limits of normal in right heart function and pulmonary circulation
hemodynamics during exercise in a large cohort of healthy individuals and elite athletes; b) inves-
tigate the impact of abnormal responses on clinical outcome in individuals with overt or at risk of
developing pulmonary hypertension.
Ferrara et al444RATIONALE
Exercise stress testing of the pulmonary circulation
to detect early-stage pulmonary vascular disease
(PVD) or any cardiac condition associated with an
increase in pulmonary venous pressure was part
of the hemodynamic work-up in the early years of
cardiac catheterization.1 After years of doubt
entertained due to insufficient knowledge of the
limits of normal, variable methodologies, and
limited validation, the advent of noninvasive exer-
cise imaging of the pulmonary vasculature and car-
diac function generated renewed interest.2–7
Currently, there is emerging consensus to define
exercise-induced pulmonary hypertension (PH)
by the presence of a restingmeanpulmonary artery
pressure (mPAP) less than 25 mm Hg and of
mPAP greater than 30 mm Hg at peak exercise,
with total pulmonary vascular resistance (PVR) of
more than 3 Wood units (WU).8,9 However, these
criteria are based on a limited number of studies
with a mixture of invasive and noninvasive ap-
proaches and variable protocols. On the other
hand, only limited information is available about
right ventricular (RV) function indices during exer-
cise testing of the pulmonary circulation,10,11 so
that the added value of these indices toac Department of Cardiology, University Hospital of Nan
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mains undefined. Thus, more methodologically
robust noninvasive exercise stress tests of the pul-
monary circulation and the right heart are needed.
Transthoracic Doppler echocardiography (TTE) is
the noninvasive method of choice because it is
part of daily cardiology practice, is flexible, and
relatively cheap, and is implemented anyway in
the diagnostic work-up of any suspicion of
PH.12–15 Current preliminary experience with exer-
cise TTE for detection or diagnosis of early PVD or
left heart conditions with increased pulmonary
venous pressure is promising.16–18 However, the
exact clinical relevance of abnormal responses in
healthy patients with a known increased risk of
developing PH and right heart failure remains un-
clear. The current state of knowledge based on re-
ported exercise TTE studies of the pulmonary
circulation and the RV in different populations are
presented in Tables 1–3.19–64 Thus, the available
literature shows great disparities in sample sizes
(from n 5 8 to n 5 113), exercise protocols (leg
press, cycle, or treadmill ergometry), timing of
measurements, selection of variables of interest,
and different work rates (ranging from 23  7 WU
up to 175  50 WU). Therefore, the need for stan-
dardization is evident. For this purpose, as recentlycy, France; ad Cardiology Unit, Surgery Department,
piratory Diseases, Monaldi Hospital, University “Fed-
Service de Cardiologie, Lune´ville, France; ag Heart
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Table 1
Pulmonary pressure response to exercise in normal subjects and athletes
Subjects:
Gender (M, F) Age (y)
Baseline
sPAP
or mPAPa
(mm Hg)
Peak
sPAP or
mPAPa (mm Hg)
Normal Subjects
Himelman et al,19 1989c 12: 1 F, 11 M 27–68 22  4 31  7
Oelberg et al,20 1998g 10: 4 F, 6 M 52.3  10.9 17  8 19  8
Bossone et al,21 1999e 14: 14 M 18.9  0.9 9 21
CI 95%:9–19
Gru¨nig et al,22 2000c 11: 11 M 37  11 27  4 36  3
Kiencke et al,23 2008c 9/— 32  3 17  3 —
Gru¨nig et al,24 2009c 191: 91 F, 100 M 32  10 20.4  5.3 35.5  5.4
Mahjoub et al,25 2009d 70: 36 F, 34 M 48  16 27  4 51  9
Mo¨ller et al,26 2010c 88: 49 F, 30 M 18.3  3.5 21.8  3.6 39 (17–63)
Argiento et al,27 2010f 25: 12 F, 13 M 36  14 19  5 46  11
La Gerche et al,28 2010c 15/2 F/13 M 38  6 21.6  3.8 47.0  6.5
D’Alto et al,29 2011c 88: 78 F, 10 M 55.3  12.4 20.6  3.7 25.9  3.3
Argiento et al,30 2012f 124: 62 M, 62 F 37  13 15.5  2.6 Ma 36.0  5.9 Ma
15.1  2.9 Fa 30.5  7.2 Fa
Lalande et al,31 2012f 24: 6 F, 18 M 25  6 23  3 61  5
Simaga et al,32 2015d 30 Blb — 16  8a 34.7  6.2a
30 Whb 16.6  2.3a 38.5  5.5a
Forton et al,33 2016g,f,c 30: 15 F, 15 M 23  2 15.4  1.2a,g 34.2  3.6a,g
15.5  1.3a,f 34.3  3.8a,f
15.5  0.8a,c 34.3  3.2a,c
Faoro et al,34 2017f 38: 5 F, 33 M 38  6 17.7  2a,sea level 44.9  4.4a,sea level
20  2.8a,altitude 47.6  4.9a,altitude
Motoji et al,35 2017f 26: 14 F, 12 M 22  3 15.8  1a 28.8  3.2a
Athletes
Bossone et al,21 1999e 26: 26 M 20.3  1.7 21 41
CI 95%:21–41
La Gerche et al,28 2010d 40/4 F/36 M 36  8 21.5  3.8 60.7  12.4
Bidart et al,36 2007e 15/— 38.7 19.4 54.8
Abbreviations: Bl, black; F, female subject; M, male subject; sPAP, systolic PAP; Wh, white; —, not available.
a mPAP (mm Hg) was calculated as 0.6  sPAP 1 2.
b 30 black subjects (age 27 6M, 25 6 F) of sub-Saharan descent and 30matched by age, sex, and body size European
white subjects (age 27  6 M, 27  8 F).
c Exercise protocol: supine.
d Exercise protocol: semisupine.
e Exercise protocol: recumbent.
f Exercise protocol: semirecumbent.
g Exercise protocol: upright bicycle.
The Right Heart International Network (RIGHT-NET) 445argued, a series of methodological requirements
can be determined from sound physiologic princi-
ples and previously available experience8,9,16:
 Exercise must be dynamic (cycling, running)
because resistive or static exercise (weight
lifting, handgrip) is associated with increases
in cardiac output (CO) too small to obtain a
meaningful range of pulmonary vascular
pressure-flow relationships.35Downloaded for Anonymous User (n/a) at HUNGARY - Szeged Un
For personal use only. No other uses without permission Body position does not matter because
the same slope of mPAP as a function of
CO, maximum oxygen uptake (VO2), and
maximum CO are estimated during
incremental cardiopulmonary exercise
testing in supine, semirecumbent or upright
positions. Thus the body position allowing
for the TTE approach can be used
safely.33,65iversity from ClinicalKey.com by Elsevier on January 17, 2019.
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Table 2
Pulmonary artery pressure response to exercise Doppler echocardiography in subjects with high risk
for pulmonary hypertension
Author, Year Age (y)
Baseline
sPAP
(mm Hg)
Peak
sPAP
(mm Hg)
Associated Disease
Subjects: Gender
Lung disease
Himelman et al,19
1989g
COPD 32–80 46  20 83  30
36: 15 F, 21 M 22  4 (ctrl) 31  7
Rodrı`guez et al,37
2017
COPD 68  9 31  27 57  29
81: 15 F, 66 M
Congenital heart disease
Oelberg et al,20
1998k
Asymptomatic ASD 52.9  11.2 31  8 51  10
10: 4 F, 6M 17  8 (ctrl) 19  8
Mo¨ller et al,26
2010g
ASD and VSD 17.5  3.3 20.7  5.3 37 (24–76)
44: 25 F, 19 M 21.8  3.6 (ctrl) 39 (17–63)
Ait Ali et al,38
2014g
Operated Fallot 26.2  11.3 49  22.4 79.4  34.2
123: 41 F, 82 M
Brenner et al,39
2015g
HA dwellers PFO
(n 5 18)
54.2  10.3 24.4  5.3 (HA PFO) 49.9  9.6
HA dwellers no PFO
(n 5 39)
49.6  10.7 24.8  3.6 (HA no
PFO)
40.3  9.1
Van Riel et al,40
2015
ASD, VSD, PDA, other 43.2  14.5 27.5  5.2 40.2  6.6
76: 50 F, 26 M 37.1  7.9 59.3  8.5
CMS
Stuber et al,41
2010g
CMS subjects 47  13 30.3  8 (CMS) 56.4  19 (CMS)
30: — 25.4  4.5 (ctrl) 39.8  8 (ctrl)
Groepenhoff
et al,42 2012g
CMS subjects (13:
13 M)
50  3 26 ± 2 (CMS) 56 ± 4 (CMS)
HA dwellers (15: 6 F,
9 M)
41  2 23 ± 1 (HA) 42 ± 3 (HA)
L (15: 6 F, 9 M) 35  3 20 ± 1 (L)sea level 31 ± 2 (L)sea level
Pratali et al,43
2013g
CMS subjects (n5 46) 51  10 30  6 (CMS) 50  12 (CMS)
HA dwellers (n 5 40) 48  8 27  5 (HA) 38  8 (HA)
HAPE-S
Gru¨nig et al,22
2000g
HAPE-S 45  8 28  4 55  11
9: — 27  4 (ctrl) 36  3
Kiencke et al,23
2008g
HAPE-S 33  2 19  4 23  6
10: — NA 17  3 (ctrl) 11  5
Relative of iPAH
Gru¨nig et al,22
2000g
Relatives of iPAH
cases
NA 24  4 (nr) 37  3 (nr)
52: — 23  3 (ar) 56  11(ar)
Gru¨nig et al,24
2009g
Relatives of iPAH
cases
37  16 20.7  5.4 39.5  5.6
291: 125 F, 166 M 20.4  5.3 (ctrl) 35.5  5.4
Connective tissue disease
Collins et al,44
2006l
Scleroderma 53.9  12.0 24  8 38  12
51: 49 F, 2 M NA
Alkotob et al,45
2006l
Scleroderma 51  12 25  8 39  8
65: 56 F, 9 M NA
Steen et al,46 2008l Scleroderma NA 34.5  11.5 51.4
54: 51 F, 3 M
(continued on next page)
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Table 2
(continued )
Author, Year Age (y)
Baseline
sPAP
(mm Hg)
Peak
sPAP
(mm Hg)
Associated Disease
Subjects: Gender
Reichenberger
et al,47 2009g
Scleroderma 54  11 23  8 40  11
33: 31 F, 2 M NA
Kovacs et al,48
2010g
Connective tissue
disease
54  11 27  5a 55  10a
52: 42 F, 10 M 23  3b 29  8b
D’Alto et al,29
2011g
Systemic sclerosis 51.8  21.5 26.2  5.3 36.9  8.7
172: 155 F, 17 M 20.6  3.7 (ctrl) 25.9  3.3
Gargani et al,49
2013h
Systemic sclerosis 58  13 — TRV 332 cm/s
164: 150 F, 14 M Range 185–533
Gru¨nig et al,50
2013g
PAH, CTPEH 54  16 64  17 98  25
124: 87 F, 37 M
Codullo et al,51
2013g
Systemic sclerosis 55.2  13 23.7  8.1e 33.1  12.6e
170: 153 F, 17 M NA 29.5  5.5f 47.7  12.2f
Voilliot et al,52
2014h
Systemic sclerosis 54  3 25  7 46  14
45: 34 F, 11 M
Nagel et al,53 2015i Systemic sclerosis 58  14 25.6  7.3c 49.9  12.7c
76: 64 F, 12 M 1.8  0.2 52.0  18.0d 83.9 18.9d
Kovacs et al,54
2017j
Systemic sclerosis 51.3  11.5m 25.0 (22.0–27.0)m 43.2  11.7m
58: 56 F, 2 M 55.3  11.6n 25.0 (22.8–30.0)n 49.5  10.7n
Bold type values indicate mPAP (mm Hg) calculated as 0.6  sPAP 1 2.
Abbreviations: ar, abnormal response to exercise; ASD, atrial septal defect; CMS, chronic mountain sickness; COPD,
chronic obstructive pulmonary disease; ctrl, controls; HA, high altitude; HAPE-S, high altitude pulmonary edema suscep-
tible; iPAH, idiopathic pulmonary arterial hypertension; nr, normal response to exercise; L, lowlanders; NA, not available;
PDA, patent ductus arteriosus; PFO, patent foramen ovale; VSD, ventricular septal defect.
a Exercise sPAP greater than 40 mm Hg.
b Exercise sPAP less than 40 mm Hg, peak VO2 less than 75%.
c No PH group of 54 subjects (mPAP <25 mm Hg).
d 22 subjects with manifest PH (mPAP >25 mm Hg).
e Subjects (n 5 164) with complete follow-up who did not develop PH.
f Subjects (n 5 6) who did develop PH.
g Exercise protocol: supine.
h Exercise protocol: semisupine.
i Exercise protocol: recumbent.
j Exercise protocol: semirecumbent.
k Exercise protocol: upright bicycle.
l Exercise protocol: treadmill.
m Exercise protocol: baseline examination.
n Exercise protocol: follow-up w4 y after their baseline examination.
The Right Heart International Network (RIGHT-NET) 447 Measurements should be made during,
not after, the exercise stress because too-fast
postexercise recovery of vascular pressures
and flows normally occurs within minutes.30,66
 Exercise stress should be incremental, with
stepwise increase in workload allowing for
measurements in quasi-steady-state VO2,
after 2 to 5 minutes of stabilization at
each step and increments in workload individ-
ually tailored to obtain at least 3 (but preferably
5) pressure-flow coordinates in an exercise
duration of less than 12 to 15 minutes.4,5,9
 It is important to estimate all the components of
PVR, thus pulmonary artery pressure (PAP),Downloaded for Anonymous User (n/a) at HUNGARY - Szeged 
For personal use only. No other uses without permisswedged PAP (PAWP), and CO. Using workload
or VO2 as surrogates for CO greatly decreases
the accuracy and precision of pulmonary
vascular function asdefinedbymPAP–CO rela-
tionships. The relationships between CO, VO2,
and workload are near-linear but with a pla-
teauing at high levels of exercise, and predic-
tion equations based on linear regression also
fail due to the considerable variability of CO at
any given level of workload or VO2.
30,33
Noninvasive exercise stress testing of the pulmo-
nary circulation using TTE is acceptable because
exercise measurements are probably accurate.University from ClinicalKey.com by Elsevier on January 17, 2019.
ion. Copyright ©2019. Elsevier Inc. All rights reserved.
Table 3
Pulmonary pressure response to exercise Doppler echocardiography in left heart diseases and valvular
heart diseases
Author, Year
Subjects,
Gender (M, F) Age (y)
Baseline sPAP
(mm Hg)
Peak sPAP
(mm Hg)
Heart Failure
Lancellotti et al,55 2003d Survivors 89: 60 M 65  11 26  10 44  18
Nonsurvivors 9: 6 M 69  9 22  9 48  16
Tumminello et al,56 2007c 46: — 66  10 31  11 52  18
Ennezat et al,57 2008d 104: 29 F, 75 M 54  12 29  9 44  18
Marechaux et al,58 2008d 85: 21 F, 64 M 57  13 27  8 43  18
Bandera et al,59 2014d 136a: 50 F, 86 M 64  11 — —
Group Ab 36: 20 F 67  10 37  17 61  19
Group Bb 100: 30 F 61  12 33  14 51  18
Guazzi et al,60 2016d 97: 20 F, 67 M 64  11 37  16 59  18
Degenerative Asymptomatic Mitral Regurgitation (at least moderate)
Magne et al,61 2010d 78: 34 F, 44 M 61  13 39  11 62  17
Kusunose et al,62 2013 196: 70 F, 126 M 56  13 39  8 56  13
Asymptomatic Severe Aortic Stenosis
Lancellotti et al,63 2012d 105: 53 F, 62 M 71  9 38  8 62  16
Asymptomatic Mitral Stenosis
Brochet et al,64 2011c 48: 32 F, 16 M 51  14 36  5 68  7
a The underlying diseases were heart failure with reduced (n5 54, 40%) or preserved ejection fraction (n5 8, 6%), history
of stable coronary artery disease (n 5 18, 13%), high-risk subjects with hypertrophic cardiac remodeling (n 5 33, 24%),
hypertrophic or restrictive cardiomyopathy (n 5 5, 4%), and mitral or tricuspid valvular regurgitation (n 5 18, 13%).
b D oxygen consumption (VO2)/D work rate: flattening (group A), not flattening (group B).
c Exercise protocol: semisupine.
d Exercise protocol: tilting bicycle.
Ferrara et al448The reliability of exercise TTE of the pulmonary cir-
culation is still under discussion, although average
responses and derived limits of normal seem to
agree very well with those obtained during a right
heart catheterization.4,5,48 Bland-Altman analysis
of PAP, PAWP, and CO measured at rest by TTE
versus right heart catheterization show almost no
bias, indicating excellent accuracy; however, limits
of agreement are sometimes wide, indicating
possible problems of insufficient precision for indi-
vidual decision-making.67 Echocardiographic esti-
mates of PAP from the maximum velocity of
tricuspid regurgitation (TR) compared with inva-
sively measured PAP during exercise have recently
also been shown by Bland-Altman analysis to be
associated with only minimal bias, demonstrating
acceptable accuracy; however, limits of agreement
were broad, indicating limited precision.11,68
Furthermore, the agreement between TTE and
invasive measures of PAP during upright exercise
is good among the subset of patients with high-
quality TR Doppler signal.68 There still is a concern
that TTE might underestimate CO during exer-
cise.11 This can probably be overcome by intensive
training of dedicated operators. Even so, a 5%Downloaded for Anonymous User (n/a) at HUNGARY - Szeged Univer
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measurements of CO by the Innocor device (by
rebreathing of nitrous oxide and sulfur hexafluoride)
and TTE of the left ventricular outflow tract in 10
subjects reported by Forton and colleagues.33
At this stage, knowledge regarding limits of
normal of exercise TTE indices of RV function is
limited to measurements of tricuspid annular plane
systolic excursion (TAPSE), tricuspid annulus S0,
and stroke volume (SV), along with estimates of
systolic PAP (sPAP) in 90 healthy young adults
(45 male subjects).10 Changes from rest to
maximum workload were (D) 4 to 10 mm for
TAPSE, 6 to 14 cm per second for S0, 12 to
57 mm Hg for sPAP, 0 to 96 mL for SV, and
0.6 plus or minus 0.3 (1.3  0.4–0.7  0.2)
mm/mm Hg for TAPSE/sPAP.THE RIGHT HEART INTERNATIONAL
NETWORK
The Right Heart International Network (RIGHT-
NET) is a large prospective observational multi-
center clinical study, including resting and
exercise TTE performed at different Europeansity from ClinicalKey.com by Elsevier on January 17, 2019.
pyright ©2019. Elsevier Inc. All rights reserved.
The Right Heart International Network (RIGHT-NET) 449and American centers (ClinicalTrials.gov identifier:
NCT03041337).
Aims
The aims of this study are
1. To evaluate the feasibility of exercise TTE for
the noninvasive assessment of the right heart
and pulmonary circulation in a large cohort of
healthy subjects, elite athletes, and subjects
with overt or at risk of PH.
2. To explore the physiologic spectrum of re-
sponses of the right heart and pulmonary circu-
lation during an optimally standardized
exercise TTE in a large cohort of healthy sub-
jects, elite athletes, and subjects with overt
PH or at risk of PH.
3. To systematically compare the morphologic
and functional behavior of the right heart and
pulmonary circulation to exercise in subjects
with normal versus abnormal responses, and
their clinical correlations.
4. To investigate the prognostic impact of an
abnormal right heart and pulmonary circulation
response to exercise during a long-term follow-
up.
Methods
Study population
It is anticipated that the study population will
comprise approximately 3000 subjects (18 years
old): 500 healthy subjects, 500 elite athletes, and
about 2000 subjects with overt PH or at risk of PH.
Healthy subjects Healthy volunteers (or subjects
for work ability assessment) with no structural
heart disease on TTE and without a history of any
cardiovascular disease and/or any systemic dis-
eases known to affect the cardiovascular system
will be prospectively recruited. Exclusion criteria
will be systemic arterial hypertension, diabetes
mellitus, coronary artery disease, significant (at
least moderate) valvular heart disease, congenital
heart disease, history of congestive heart failure,
cardiomyopathies, sinus tachycardia, atrial fibrilla-
tion or flutter, use of illicit drugs, medical therapy
with cardioactive drugs, chronic excessive alcohol
consumption, elite athletes, pregnancy, obesity
(body mass index30 kg/m2), pulmonary disease,
renal disease, hepatic disease, significant endo-
crine alterations, cancer, and inadequate echocar-
diographic image quality.69
Elite athletes Cardiac adaptations in athletes
mainly depend on the characteristics, intensity,
and cumulative duration of training protocols,
with a dose-effect relation.70,71 In particular,Downloaded for Anonymous User (n/a) at HUNGARY - Szeged 
For personal use only. No other uses without permissisotonic (dynamic) exercise is associated with a
substantial increase in CO and reduction in periph-
eral vascular resistance; therefore, endurance
training mainly results in volume overload.
Conversely, isometric (static) exercise is charac-
terized by less increase in CO and by a transient
increase in peripheral resistance; therefore, its
training is characterized by a pressure overload.71
In this study, protocol activity levels will be
assessed by questionnaire, and subjects will be
asked to describe and quantify exercise during a
typical week during the preceding months. All the
athletes will have been trained intensively for 15 to
20 hours per week for at least 4 years.72 Based
on their training protocol and the type of sports ac-
tivity, they will be categorized into 2 groups:
endurance-trained athletes and strength-trained
athletes.72–74 Endurance-trained athletes (long-dis-
tance and middle-distance swimming or running,
cycling, rowing) will be defined as subjects actively
engaged in endurance sports competition, sub-
jected to intensive aerobic isotonic dynamic exer-
cise at incremental workloads of 70% to 90% of
maximal heart rate. In particular, they should have
performed 3 hours per day of incremental long-
distance swimming (7000 m per day divided into
a series of 400–800 m) or 3 hours per day of long-
distance running or cycling, and only 2 hours per
week of weight-lifting at a low workload.70 On the
other hand, the strength-trained athletes group
will include top-level competitive athletes (weight-
lifting, martial arts, windsurfing) who should have
undergone an aerobic isometric static exercise at
incremental workloads of 40% to 60% of maximal
heart rate. Their training protocol should have
included 3 hours per day of short-distance running
and/or 4 hours per day of weight-lifting at a high
workload.72–74Patients with overt pulmonary hypertension or at
risk of pulmonary hypertension Patients with
overt or at risk of PH will be classified according
to European guidelines.12
1. Pulmonary arterial hypertension (PAH): idio-
pathic, heritable, healthy relatives of patients
with PAH, healthy carriers of mutations of bone
morphogenetic receptor 2 gene, associated
with connective tissue disease, portal hyperten-
sion, schistosomiasis, congenital heart disease
2. PH due to left heart disease: left heart valve dis-
ease, heart failure with reduced or preserved
ejection fraction, congenitally acquired inflow
or outflow tract obstruction, and congenital
cardiomyopathies
3. PH due to chronic lung diseases and/or
hypoxia: chronic altitude exposure, chronicUniversity from ClinicalKey.com by Elsevier on January 17, 2019.
ion. Copyright ©2019. Elsevier Inc. All rights reserved.
Ferrara et al450obstructive pulmonary disease, interstitial lung
diseases, sleep-disordered breathing
4. Chronic pulmonary thromboembolic disease
and other pulmonary artery obstructions
5. PH with unclear and/or multifactorial mecha-
nisms: miscellaneous conditions such as
histiocytosis-X or sarcoidosis.
Clinical data
Demographic characteristics, complete medical
history, comorbidities, symptoms and signs, labo-
ratory values, electrocardiogram (ECG) parame-
ters, coronary angiography and other imaging
results, medications, and in-hospital and long-
term outcomes will be systematically collected
for all patients via standardized forms to obtain
as much information as possible (Table 4). Spe-
cific attention will be paid to excluding the pres-
ence of any pulmonary condition (apart from
patients with PH due to chronic lung diseases
and/or hypoxia) that may lead to a pathologic pul-
monary hemodynamic response during exercise.
Follow-up would be performed at 6 months and
then once a year for at least 5 years during outpa-
tient clinical visits or by telephone call. EventsTable 4
Clinical data
Demographic and
Age (y) Sex
Height
(cm)
Weight
(kg)
BMI
(kg/m
Systolic BP
(mm Hg)
HR Diastolic BP
(mm Hg)
Physical activity Coff
Alco
Cardiovascular
Diabetes
Arterial
Hypertension Dy
Previous
cardiovascular
events or
interventions
— —
Laborator
Glycaemia
(mg/dL) Cholesterol (mg/dL) HDL (mg/dL)
CRP (m/dL) Iron (mg /dL) Creatinine (mg/d
Other Data (if
Pulmonary
Functional Test
Capillarosco
Pattern
6MWT (mt) Other imagin
Abbreviations: BMI, body mass index; BNP, B-type natriuretic p
reactive protein; Hb, hemoglobin; HDL, high-density lipoprote
uretic peptide; SSC, scleroderma; 6MWT, 6 minutes walking te
Downloaded for Anonymous User (n/a) at HUNGARY - Szeged Univer
For personal use only. No other uses without permission. Corecorded will be death, major cardiovascular
events (myocardial infarction, stroke, coronary
revascularization, acute heart failure), hospitaliza-
tion, and diagnosis of PH by invasive recording
of an mPAP greater than 25 mm Hg at rest.
Resting echocardiographic Doppler
examination
TTE examinations will be performed at rest with
commercially available equipment on all subjects,
according to standardized protocols.75 A detailed
case report form (CRF) will be used by all labora-
tories. All the measurements included in the CRF
will be assessed by the operators and performed
according to the recommendations for echocar-
diographic assessment of the left and right heart
from the American Society of Echocardiography
or the European Association of Cardiovascular Im-
aging76–78 (Table 5).
Exercise echocardiographic Doppler
examination
Exercise TTE will be performed according to the
current recommendations on a semirecumbent
cycle ergometer with an incremental workloadLifestyle Data
2)
BSA
(m2)
Waist
(cm)
ee
hol
Smoker Drugs and
toxins
Other lifestyle
information
Risk Factor
slipidemia Comorbidities Medical Therapy
— —
y Data
Triglycerides (mg/dL) Troponin Hb (g/dL)
L) NT-proBNP (pg/ml)
BNP (pg/mL)
Other laboratory
examination
Available)
py Specific Antibodies
for SSC
g data Other useful
information
eptide; BP, blood pressure; BSA, body surface area; CRP, C-
in; HR, heart rate; NT-proBNP, N-terminal pro b-type natri-
st.
sity from ClinicalKey.com by Elsevier on January 17, 2019.
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Table 5
Key echocardiographic measurements at rest and during exercise
Echocardiographic View Measurement
Parasternal long axes  LV end-diastolic diameter
 LV end-systolic diameter
 Interventricular septum thickness (diastole)
 Inferolateral wall thickness (diastole)
 LVOT diameter (zoom)
 Wall motion abnormalities
 Aortic and mitral function
 Pericardial effusion
Parasternal short axes  RVOT diameter
 Pulmonary artery diameter
 RVOT acceleration time
 RVOT TVI notch
 PR early diastolic velocity
 Peak tricuspid velocity
 Wall motion abnormalities
 Aortic, mitral, tricuspid and pulmonary valve function
 Pericardial effusion
Apical 4-chamber  LV end-diastolic volume
 LV end-systolic volume
 Wall motion abnormalities
 LA volume
 E, A, deceleration time
 e’ TDI lateral
 e’ TDI septal
 S0 systolic TDI
 Mitral and tricuspid function
 Pericardial effusion
Apical 5-chamber  Peak aortic velocity
 LVOT TVI
 Aortic valve function
Apical 2-chamber  LV end-diastolic volume
 LV end-systolic volume
 Wall motion abnormalities
 LA volume
 Mitral valve function
 Pericardial effusion
Focused apical on the RV  RV dimension 1
 RV dimension 2
 RV diastolic area
 RV systolic area
 RA volume
 TAPSE
 Peak tricuspid velocity
 E, A
 S0 systolic TDI
 e’ TDI, a’ TDI
 Tricuspid valve function
 Pericardial effusion
Subcostal  IVC diameter
 IVC collapse
 RV free wall thickness
 Pericardial effusion
Abbreviations:A,mitral inflowE velocity asmeasuredby PWDoppler; E,mitral inflowE velocity asmeasuredby PWDoppler;
e’, early diastolic velocity of themitral annulus as measured by tissue Doppler; IVC, inferior vena cava; LA, left atrial; LV, left
ventricular: LVOT, left ventricular outflow tract; PR, pulmonary regurgitation; RA, right atrial; RVOT, RV outflow tract;
S’ pulsed Tissue Doppler velocity of lateral tricuspid annulus; TDI, tissue Doppler imaging; TVI, time-velocity integral.
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Fig. 1. Relationship between mPAP and CO at rest and during incremental exercise in 3 different diseases
compared with normal response to exercise in an age-matched healthy control. (A1–A4) A 53-year-old woman
with scleroderma (New York Heart Association [NYHA] class II). (B1–B4) A 64-year-old woman with patent ductus
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Fig. 2. Methodology of exercise stress echocardiography. Agitated salinemay be used bymixing saline solution with
room air (9:1 ratio) and vigorously agitating between 2 syringes using a 3-way stopcock, in cases of poor TR Doppler
signals. A 5-mL bolus will be rapidly administered during exercise while simultaneously obtaining images of the right
and left heart in the apical 4-chamber view. For each echocardiographic (echo)-Doppler parameter in case of poor
and/ormissing images itwill be indicatednot feasible and/or not assessed, respectively. Key echo-Doppler parameters
that will be measured are specified in Tables 5 and 6. 2D, 2-dimensional; E, mitral inflow E velocity as measured by
pulsed-wave Doppler; e’, early diastolic velocity of the lateral mitral annulus and septal (average) as measured by
TDI; LVOT, left ventricular outflow tract; PASP, pulmonary artery systolic pressure; RVOT, right ventricular outflow
tract; TDI, tissue Doppler imaging (pulsed Doppler sample volume is placed at the tricuspid annulus, interventricular
septum, and lateralmitral annulus in the apical 4-chamber view); TRV, tricuspid regurgitant velocity; VTI, velocity time
integral; * RVOT VTI will be measured only at rest, peak exercise and after 5-minutes recovery.
The Right Heart International Network (RIGHT-NET) 453of 25 every 2 minutes up to the symptom-limited
maximal tolerated workload.18,27,79 In subjects
with reduced functional capacity, the exercise
protocol may consist of lower incremental work-
load (10–20 WU every 2 minutes), and will
be specified in the records. The exercise table
will be tilted laterally by 20 to 30 to the left.
Heart rate (ECG lead) will be continuously moni-
tored, and blood pressure will be monitored by
sphygmomanometer at baseline and during the
last 15 seconds of each workload step. Termina-
tion criteria and/or positive test criteria for induc-
ible myocardial ischemia will follow the current
recommendations.18,79 Key echocardiographic=
arteriosus, not corrected (NYHA class II). (C1–C4) A 75-year-
III) with midrange reduced ejection fraction of 46%. The D
derma (D), 5.5 mm Hg/L/min in patient with congenital he
patient (>) are indicative of an abnormal pulmonary v
response in healthy control (,) (D mPAP/D CO of 2 mm
Hg) 5 0.6  sPAP 1 2; SV 5 p  (LVOT/2)2  LVOT VTI; C
CHF, chronic heart failure; CTD, connective tissue disea
velocity integral. (Courtesy of Echo Lab Cava de’ Tirreni an
pital of Salerno, Italy.)
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For personal use only. No other uses without permissmeasurements will be acquired at baseline, at
50 WU, at peak exercise, and after 5-minutes re-
covery, including left ventricular and RV function,
valvular and subvalvular gradients, regurgitant
flows, left and right heart hemodynamics
(sPAP, mPAP, PCWP, PVR, right atrial pressure
[RAP] and CO) (Figs. 1 and 2, see Table 5;
Table 6).
Oxygen saturation
Transcutaneous arterial oxygen saturation will be
measured at a fingertip with a pulse oxymeter at
baseline, 50 WU, peak exercise, and after 5-mi-
nutes recovery.old woman with diagnosis of heart failure (NYHA class
mPAP/D CO of 3.4 mm Hg/L/min in patient with sclero-
art disease (), and 15.8 mm Hg/L/min in heart failure
ascular response to exercise compared with normal
Hg/L/min; normal ranges from 0.5 to 3.0). mPAP (mm
O (L/min) 5 SV  HR. CHD, congenital heart disease;
se; LVOT, left ventricular outflow tract; TVI, time-
d Amalfi Coast Division of Cardiology, University Hos-
University from ClinicalKey.com by Elsevier on January 17, 2019.
ion. Copyright ©2019. Elsevier Inc. All rights reserved.
Table 6
Key echocardiographic indices for evaluation of the right heart pulmonary circulation unit at rest and
during exercise
Key Echo-Doppler
Indices Cut-Off Value at Rest
Cut-Off Value at Peak
Exercise Pitfalls and Remarks Reference
Pulmonary Hemodynamics
sPAP (mm Hg)
4  TRV2 1 RAP
TRV >2.8–2.9 m/s or
not measurable
sPAP >34–36 mm Hg
TRV >3.1 m/s
sPAP >40 mm Hg for
healthy patients
sPAP >55–60 mm Hg
for athletes
Signal acquisition
may be difficult
during exercise
because of
increased
respiratory rate
and excursion
Postexercise is less
reliable because
sPAP is known to
return to baseline
quite quickly
Sweep velocity
should be at least
100 mm/s
measuring only the
well-defined dense
spectral profile
If there is a weak TR
jet the intravenous
use of agitated
saline may provide
a more complete
TR envelope with
attention to
avoiding artifacts
(fringes) and
overestimation
12,18,21,30,68,76
RAP (mm Hg)
IVC size and
collapsibility
<2.1 cm,
collapse >50%:
RAP 5 3–5 mm Hg
— The baseline RA
pressure is used for
all calculations
because of the
difficulty of
imaging the IVC
and estimating RA
pressure during
exercise
This assumption may
result in
underestimation
of sPAP
18,76
mPAP (mm Hg)
(0.6 
PASP 1 2) 1 RAP
25 mm Hg 34 mm Hg at a
CO<10 L/min,
45 mm Hg at a
CO<20 L/min and
52 mm Hg at a
CO<30 L/min
mPAP–CO
relationship is
preferable for
studying the
pulmonary
vascular response
to exercise
30
(continued on next page)
Ferrara et al454
Downloaded for Anonymous User (n/a) at HUNGARY - Szeged University from ClinicalKey.com by Elsevier on January 17, 2019.
For personal use only. No other uses without permission. Copyright ©2019. Elsevier Inc. All rights reserved.
Table 6
(continued )
Key Echo-Doppler
Indices Cut-Off Value at Rest
Cut-Off Value at Peak
Exercise Pitfalls and Remarks Reference
CO (L/min)
SV*HR/1000
SV 5 p,(LVOT/
2)2,LVOT VTI
SV 5 60–120 mL
CO 5 4–8 L/min
Flow
reserve5 SV 20%
CO tends to be
underestimated,
mainly because of
the
underestimation
of LVOT
dimensions
LVOT PW Doppler
sample volume
should be placed
as much as possible
at the same
position in the
LVOT during test
18
PVR
TRV/VTI RVOT (cm)
 10 1 0.16
<1.5 WU normal PVR >3 WU Methods for
estimating PVR are
less well-validated
Should not be used
as a substitute for
the invasive
evaluation of PVR
PVR at peak exercise
is flow-dependent
Dynamic PVR may
better represent
PVD than total PVR
at peak exercise
4,12,76
ATRVOT <100 m/s — Heart rate should be
in the normal
range of 60 to
<100 beats/min
76
FVERVOT Midsystolic notching — Lack of data in wide
population of PH
subjects and
during exercise;
not specific for
thromboembolic
diseases
76
E/e’
LAP 5 1.9 1
1.24 E/e’
Average E/e’ratio <10
LAP >15 mm Hg
All the 3 conditions:
Average E/e’ >14 or
septal E/e’
ratio >15, peak
TR
velocity >2.8 m/s
and septal e’
velocity <7 cm/s
Angle-dependent;
proper attention
to the location of
the sample size.
Mitral inflow and
annular early and
late diastolic
velocities are
frequently fused at
peak exercise it is
preferable to
acquire Doppler
signal when the HR
is slower than 100–
110 beats/min
78
(continued on next page)
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Table 6
(continued )
Key Echo-Doppler
Indices Cut-Off Value at Rest
Cut-Off Value at Peak
Exercise Pitfalls and Remarks Reference
RV function
TAPSE <16 mm Mean  SD (range)
34  2 (30–38)
D 5 7  2 (3–11)
<19 mm in primary
MR
Angle- and load-
dependent; not
fully
representative of
RV global function
There are no well-
defined reference
values to assess RV
contractile reserve
with exercise
10,18,69,76
RV FAC
100  (EDA 
ESA)/EDA
<35% Mean  SD (range)
53.7  6.4 (40.9–
66.5)a
Poorly reproducible
in case of
suboptimal image
quality especially
during exercise
There are no well-
defined reference
values to assess RV
contractile reserve
with exercise
76
S0 TDI <10 cm/s Mean  SD (range)
25  4 (18–29)
D 5 10  2 (6–14)
Angle-dependent;
not fully
representative of
RV global function
There are no well-
defined reference
values to assess RV
contractile reserve
with exercise
10,76
RV-PV coupling
TAPSE/PASP ratio <0.5 for healthy Mean  SD (range)
0.7  0.2 (0.3–1.1)
D50.6 0.3 (1.2–
0)
Conceptually, the
lower the ratio, the
worse the
association of PH
and RV
dysfunction
10,60,69
DmPAP/DCO
mm Hg/L1/min1
— >3 abnormal
pulmonary
vascular reserve
An increase in mPAP
of 1–2 mm Hg/l/
min of CO
represents a
normal pulmonary
vascular response
Does not clarify
whether the
abnormal pressure
is attributable to
PVD or upstream
transmission of a
high LAP
4,30
(continued on next page)
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Table 6
(continued )
Key Echo-Doppler
Indices Cut-Off Value at Rest
Cut-Off Value at Peak
Exercise Pitfalls and Remarks Reference
RVESPAR
sPAP/RV end-systolic
area
— — The ratio of peak
exercise to resting
RVESPAR may be a
promising
noninvasive index
of RV contractile
reserve. A ratio of
1.64 had respective
sensitivity and
specificity of 82%
and 96% (AUC 0.94
[95% CI: 0.87–
1.02]) for
identifying CTEPH
patients
RVESPAR correlate
strongly with data
obtained by
ExCMR
11
Abbreviations: AT, acceleration time (by PW Doppler); CTEPH, chronic thromboembolic PH; CO, SV*HR/1000; E, mitral
inflow E velocity as measured by PW Doppler; e’, early diastolic velocity of the mitral annulus as measured by TDI;
EDA, end-diastolic area; ExCMR, exercise cardiac magnetic resonance; FAC, fractional area change; HR, heart rate; LAP,
LA pressure; PASP, pulmonary artery systolic pressure; PV, pulmonary vascular; PW, pulsed-wave; RAP, RA pressure; RVES-
PAR, RV end-systolic pressure-area ratio; SV, stroke volume; TRV, TR peak velocity; VTI, velocity-time integral.
a Exercise stress test was performed to maximum exercise tolerance on a graded treadmill.
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All participating centers will be chosen according
to recommended standard operational proced-
ures in terms of data imaging acquisition (opera-
tional modes, machine settings), data storage
(data format, transfer procedure), and data pro-
cessing (software used and measurement proced-
ures). All participating centers will fulfill established
advanced standard criteria for echocardiographic
laboratories.80 All echocardiographic recordings,
both at rest and exercise, will be reviewed and
analyzed off line by certified operator experts in
TTE. A quality control procedure will be set to
reduce variability among laboratories and opera-
tors and to maintain and improve the quality of
subsequent collections of data.81 The Echo Core
Lab will be established with 3 certified cardiolo-
gists, experts in TTE, and with specific docu-
mented experience in patients with PH. The Echo
Core Lab will issue a user manual with a detailed
description on how tomeasure each single param-
eter, according to the most recent American and
European recommendations and guidelines.76–81
The user manual will be sent to all participating
centers and will be the reference for TTE assess-
ment. All operators participating in the study who
will be in charge of taking measurements on theDownloaded for Anonymous User (n/a) at HUNGARY - Szeged 
For personal use only. No other uses without permissechocardiographic examinations will undergo
quality control consisting of 2 steps. For step 1
(Fig. 3), each year the Echo Core Lab will prepare
20 multiple-choice questions on a dedicated on-
line questionnaire. All participating centers will be
invited by email to access the questionnaire (pass-
word protected). Questions will address echocar-
diographic issues, especially about the right
heart and noninvasive hemodynamics. At least
18 out of 20 correct answers are needed to pro-
ceed to step 2. The Echo Core Lab will provide
dedicated personal feedback to the participating
centers, when needed. For step 2 (Fig. 4), each
year the Echo Core Lab will send a compact disc
(CD) with 10 complete echocardiographic exami-
nations in DICOM format, including resting, 50
W, peak stress, and recovery acquisition in the
whole spectrum of enrolled subjects (healthy sub-
jects, elite athletes and patients with overt and at
risk of PH). All images and videos will be
completely anonymized to protect subjects’ pri-
vacy. All operators will be requested to measure
a prespecified set of data, including all parameters
listed in the CRF (see Tables 4 and 5). The opera-
tors will directly measure the requested parame-
ters by uploading the 10 cases from the CD to
their echocardiographic machine. The DICOMUniversity from ClinicalKey.com by Elsevier on January 17, 2019.
ion. Copyright ©2019. Elsevier Inc. All rights reserved.
Fig. 3. Quality control step 1.
Ferrara et al458format will easily allow the measurement proced-
ure. All operators will be then asked to enter their
measurements in a dedicated Excel file, which
will be then sent to the coordinating center for
analysis. The gold standard value for each mea-
surement will be established according to the
reading of the Echo Core Lab (by unanimous
approval). The Echo Core Lab will also establish
acceptable ranges for correct measurement of
continuous parameters, when appropriate. Intra-
observer and interobserver variability will then be
estimated. Intraclass correlation coefficient (ICC)
will be calculated, and for those operators with
an ICC less than 0.75, a second slot ofDownloaded for Anonymous User (n/a) at HUNGARY - Szeged Univer
For personal use only. No other uses without permission. Comeasurements will be requested, until a proper
agreement is reached. These operators will also
be contacted by the Echo Core Lab for personal
feedback aimed at understanding the reasons for
discrepancy. If needed, operators from the Echo
Core Lab will travel to the participating center
site for retraining to guarantee robustness in data
acquisition and analysis.DATA MANAGEMENT AND STATISTICAL
ANALYSIS
Patient data will be uploaded on a dedicated Web-
based platform with secured access credentialssity from ClinicalKey.com by Elsevier on January 17, 2019.
pyright ©2019. Elsevier Inc. All rights reserved.
Fig. 4. Quality control step 2. CD, compact disc; ICC, intraclass correlation coefficient QC, quality control.
The Right Heart International Network (RIGHT-NET) 459and protocols transporter layer security (TLS)/Hy-
perText Transfer Protocol over SecureSocket Layer
(HTTPS) and will be completely anonymized before
the processing phase by using a hashing function (a
noninvertible algorithm capable of mapping the
identification data in a unique alphanumeric string).
Dedicated technical staff with specific expertise will
ensure the correct operative functioning of the plat-
form and the safety of data will be guaranteed. Data
management and statistical analyses will be carried
out at the Institute of Clinical Physiology–consiglio
nazionale delle ricerche (CNR) inPisa, Italy. Descrip-
tive statistics will comprise of the usual scale and
frequency statistics. Data will be presented as
mean plus or minus standard deviation, or median
and interquartile ranges, as appropriate. Different
clinical conditions will be compared by 2-sided stu-
dent’s t-tests orWilcoxon rank sum tests, as appro-
priate. Correlation analysis will be performed
with Pearson or Spearman correlation analysis.
Cox regression analysis and Kaplan-Meier survival
estimation will be used to analyze mortality and
time-to-clinical-worsening or time-to-event data.Downloaded for Anonymous User (n/a) at HUNGARY - Szeged 
For personal use only. No other uses without permissP-values less than 0.05 will be considered as statis-
tically significant.
All analyses will be performed by the SPSS/PC
software package (SPSS, Chicago, IL, USA) and
GraphPad Prism (GraphPad Software Inc, San
Diego, CA, USA).LEGAL AND ETHICAL ASPECTS
The study will be performed in accordance with the
Declaration of Helsinki in its current version (2013).
Subjects of the prospective cohort will be informed
of the nature and scope of the proposed study, in
particular about the possible benefits for their
health and potential risks. They will be informed
verbally and with a special written document before
inclusion to the study. Their consent will be docu-
mented by signing the consent form. Participation
of subjects in the study is voluntary; the consent
to participate may be withdrawn at any time. In
case of withdrawal from the study, the subject
can require his or her already obtained data to be
deleted. The protocol will be submitted to the ethicsUniversity from ClinicalKey.com by Elsevier on January 17, 2019.
ion. Copyright ©2019. Elsevier Inc. All rights reserved.
Ferrara et al460committee of each participating center. Other
cooperating centers will apply for approval at their
local ethics committees. Subjects will be included
after the committee has stated no objections
against the proposed study. The name of the sub-
ject and other confidential information that are sub-
ject to medical confidentiality are subject to the
provisions of the Federal Data Protection Act and
the Data Protection Law of Baden-Wu¨rttemberg,
according to the new European Union directive of
protection of personal data (GDPR). Transfer for
analysis will be performed with pseudonym-coded
data. Personal data that may lead to identification
of the subject will not be transferred.SIDE EFFECTS AND RISKS
The risks of this study are limited to the risks associ-
atedwith a stress echocardiography,which are very
rare. Studies unanimously show the excellent safety
profile of stress echocardiography, especially with
exercise.79 Leg muscle aching might occur the
day after the diagnostic test. In some rare cases, a
transient ischemia with consequent chest pain or
ECG abnormalities could occur. Drug administra-
tion is rarely medically indicated to resolve this
side effect. In some cases, hypotension may occur
that could lead to dizziness and sweating. In the
case of premature interruption of the test, the sub-
jects will be asked to lie with legs elevated to restore
arterial pressure rapidly. In rare cases, life-
threatening arrhythmias might occur.SAFETY MEASURES
During the study procedure, an ECG will be
recorded and the blood pressure on the right arm
will be measured every 2 to 3 minutes. These mea-
sures will be performed until the subject is
exhausted or if symptoms such as chest pain or
shortness of breath occur, or if the doctor perform-
ing the examination considers it necessary to halt
the procedure due to changes in the ECG or blood
pressure. Subjects will be told to inform the doctor
immediately if any symptoms or chest pain, dys-
pnea, pain in the legs, or other discomfort occurs
during the examination. All necessary equipment
needed to perform cardiopulmonary resuscitation,
as well as medications required to manage
major medical events (eg, myocardial ischemia,
syncope, arrhythmias, lung insufficiency)will bepre-
sent in the roomwhere the stress echocardiography
will be performed. All the medical staff performing
the studywill be able to treat possible complications
and to behave properly in the very rare occurrence
of life-threatening arrhythmias. Subjects will be su-
pervised at least 30 minutes after finishing the testDownloaded for Anonymous User (n/a) at HUNGARY - Szeged Univer
For personal use only. No other uses without permission. Coand written informed consent will be obtained for
each subject.CLINICAL IMPLICATIONS
As recently reviewed,8 exercise-induced PH
defined by an abnormally high mPAP alone or in
combination with elevated PAWP and CO,
measured invasively or noninvasively, has been re-
ported in subjects susceptible to high altitude pul-
monary edema, healthy family members of
patients with idiopathic PAH, systemic sclerosis,
chronic obstructive pulmonary disease or intersti-
tial lung diseases, heart failure with decreased
or preserved ejection fraction, mitral valve dis-
ease, aortic stenosis, late closure of atrial septal
defects, and chronic thromboembolism (see Ta-
bles 1–3).19–64 Exercise-induced PH has been
typically diagnosed in patients referred for short-
ness of breath and exercise intolerance without
obvious pulmonary or cardiac cause.82 In these
patients, there is an inverse relationship between
the slope of mPAP–CO and VO2 max, suggesting
RV afterload-related limitation of maximum CO,
such as that observed in patients with manifest
PH83 and, in fact, in healthy subjects in normoxia
or in hypoxia.32,42 Thus, modulation of aerobic ex-
ercise capacity by the afterload-sensitive RV
seems to be a universal phenomenon; however,
of course, it is exacerbated in exercise-induced
PH or manifest PH compared with healthy con-
trols. Exercise-induced PH has been shown to
be a major risk factor for the development of
resting PH in patients with systemic scle-
rosis53,54,84,85 and in healthy carriers of a BMPR2
mutation.86 Exercise-induced PH has been shown
by limited size studies to be of prognostic rele-
vance in systemic sclerosis84,87 and in valvular
heart diseases, such as mitral regurgitation61,62
or aortic stenosis.63 Thus, at this stage, it remains
to be defined whether noninvasively diagnosed
exercise-induced PH with updated rigorous meth-
odology as prespecified in the RIGHT-NET pre-
dicts later development of manifest PH, clinical
deterioration, or decreased survival. It is unclear
whether exercise-induced changes in RV function
increase the prognostic relevance of exercise TTE
in evaluating the pulmonary circulation. The
RIGHT-NET protocol is expected to answer to
these questions.REFERENCES
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